IQVIA Holdings Inc. $IQV Stock Sold by One Way Holdings LLC

One Way Holdings LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 99,017 shares of the medical research company’s stock after selling 7,370 shares during the period. IQVIA accounts for approximately 1.2% of One Way Holdings LLC’s investment portfolio, making the stock its 26th largest holding. One Way Holdings LLC’s holdings in IQVIA were worth $26,621,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of IQVIA during the 3rd quarter worth approximately $12,510,000. Vise Technologies Inc. raised its position in shares of IQVIA by 17.2% during the 3rd quarter. Vise Technologies Inc. now owns 9,601 shares of the medical research company’s stock worth $2,581,000 after purchasing an additional 1,411 shares during the last quarter. Avestar Capital LLC purchased a new stake in IQVIA in the 3rd quarter valued at approximately $320,000. Parcion Private Wealth LLC increased its position in IQVIA by 13.9% during the third quarter. Parcion Private Wealth LLC now owns 1,312 shares of the medical research company’s stock worth $353,000 after buying an additional 160 shares in the last quarter. Finally, Soltis Investment Advisors LLC purchased a new position in IQVIA during the third quarter worth $461,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Trading Down 0.1%

Shares of IQV opened at $266.93 on Monday. The stock’s 50-day moving average is $266.22 and its two-hundred day moving average is $210.41. The stock has a market cap of $43.99 billion, a PE ratio of 32.43, a P/E/G ratio of 2.38 and a beta of 1.16. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.00 earnings per share. Equities analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Weiss Ratings downgraded IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research report on Wednesday. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, September 12th. Argus lifted their target price on shares of IQVIA from $215.00 to $235.00 in a research note on Tuesday, July 7th. Robert W. Baird raised their price objective on IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a report on Tuesday, October 27th. Finally, Morgan Stanley upped their target price on IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $294.21.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.